Parkinson's disease

The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.